AmCad BioMed Corporation (TPEX:4188)
Taiwan · Delayed Price · Currency is TWD 16.75
+1.50 (9.84%)
Sep 3, 2025, 1:30 PM CST
AmCad BioMed Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | -56.39 | -50.58 | -45.31 | -53.49 | -25.54 | -35.44 | Upgrade |
Depreciation & Amortization | 16.43 | 18 | 17.16 | 17.27 | 17.9 | 19.28 | Upgrade |
Other Amortization | 0.28 | 0.28 | 0.3 | 0.35 | 0.38 | 0.38 | Upgrade |
Loss (Gain) From Sale of Assets | 0.22 | 0.19 | 0.17 | 0.01 | 0.08 | 0.64 | Upgrade |
Loss (Gain) From Sale of Investments | -0.33 | -0.03 | -0 | -0.02 | -0 | -0.02 | Upgrade |
Stock-Based Compensation | 2.83 | 2.9 | 0.68 | 0.82 | 0.54 | -0.18 | Upgrade |
Provision & Write-off of Bad Debts | - | - | - | -0.05 | -0.1 | 0.1 | Upgrade |
Other Operating Activities | -6.44 | -2.31 | 2.16 | -0.86 | -1.35 | -7.63 | Upgrade |
Change in Accounts Receivable | 0.4 | -9.31 | -6.84 | 1.33 | -2.93 | 2.15 | Upgrade |
Change in Inventory | -7.55 | -11.61 | -5.41 | -2.6 | 0.02 | -2.43 | Upgrade |
Change in Accounts Payable | -0.86 | 0.9 | 0.96 | -0.21 | -0.04 | -0.4 | Upgrade |
Change in Unearned Revenue | -0.43 | -1.54 | -0.61 | -2.78 | -31.61 | -24.46 | Upgrade |
Change in Other Net Operating Assets | 0.26 | 1.25 | -4.86 | 6.03 | 3.68 | -2.05 | Upgrade |
Operating Cash Flow | -51.58 | -51.85 | -41.6 | -34.19 | -38.97 | -50.05 | Upgrade |
Capital Expenditures | -2.89 | -2.72 | -0.29 | -0.61 | -2.34 | -0.32 | Upgrade |
Sale (Purchase) of Intangibles | -0.33 | -0.33 | - | - | - | - | Upgrade |
Investment in Securities | -185.38 | -182.81 | 26.19 | 28.76 | 51.18 | 8.14 | Upgrade |
Other Investing Activities | 0.06 | 0.43 | 1.42 | -1.01 | 0.33 | -1.9 | Upgrade |
Investing Cash Flow | -188.53 | -185.43 | 27.31 | 27.14 | 49.18 | 5.92 | Upgrade |
Long-Term Debt Repaid | - | -5.25 | -4.42 | -4.42 | -4.54 | -5.02 | Upgrade |
Net Debt Issued (Repaid) | -5.25 | -5.25 | -4.42 | -4.42 | -4.54 | -5.02 | Upgrade |
Issuance of Common Stock | 230.24 | 230.63 | 1.32 | - | - | - | Upgrade |
Other Financing Activities | 0.03 | - | - | 0.01 | -6.8 | - | Upgrade |
Financing Cash Flow | 225.01 | 225.38 | -3.1 | -4.42 | -11.35 | -5.02 | Upgrade |
Net Cash Flow | -15.1 | -11.9 | -17.39 | -11.47 | -1.13 | -49.15 | Upgrade |
Free Cash Flow | -54.47 | -54.57 | -41.89 | -34.81 | -41.3 | -50.37 | Upgrade |
Free Cash Flow Margin | -124.94% | -102.76% | -64.20% | -56.48% | -48.14% | -78.77% | Upgrade |
Free Cash Flow Per Share | -0.87 | -0.95 | -0.79 | -0.65 | -0.78 | -0.95 | Upgrade |
Cash Interest Paid | 0.13 | 0.18 | 0.12 | 0.12 | 0.14 | 0.09 | Upgrade |
Cash Income Tax Paid | 0.01 | 0.01 | - | - | - | - | Upgrade |
Levered Free Cash Flow | -31.63 | -36.17 | -29.01 | -20.2 | -33.04 | -29.22 | Upgrade |
Unlevered Free Cash Flow | -31.55 | -36.06 | -28.94 | -20.13 | -32.95 | -29.16 | Upgrade |
Change in Working Capital | -8.18 | -20.31 | -16.76 | 1.76 | -30.88 | -27.19 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.